3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
18
Carcinoma, Hepatocellular
8
Liver Neoplasms
7
Colorectal Neoplasms
3
Unresectable Pancreatic Cancer
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Locally Advanced Pancreatic Cancer
2
Cholangiocarcinoma
2
Solid Tumor Including Thyroid, Bone, Liver, Pancreas
1
Rectal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Adenocarcinoma Resectable
1
Pancreatic Adenocarcinoma Locally Advanced
1
Liver Metastasis Colon Cancer
1
Liver Diseases
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Colorectal Liver Metastases
1
Bile Duct Neoplasms
1
Advanced Gastric Cancer
1
Interventions
Sorafenib
5
lenvatinib
3
sintilimab
2
pembrolizumab
2
halofantrine
2
camrelizumab
2
atezolizumab
2
Immunotherapy
2
Blood Specimen Collection
2
Bevacizumab
2
Antibodies
2
trifluridine tipiracil drug combination
1
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
linifanib
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
durvalumab
1
bavituximab
1
avelumab
1
User-Centered Design
1
Sunitinib
1
Sufentanil
1
Standard of Care
1
Shadowing Technique, Histology
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Electroporation
×
Gastrointestinal
×
Clear all
NCT07191548
2025-10-10
LIVERMET-IRE
Angiodynamics, Inc.
Phase NA
Not yet recruiting
50 enrolled